Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-4.89	2.51	6.28	33.15	23.34	115.55
Depreciation & Amortization	4.56	3.01	2.73	2.84	2.86	2.89
Share-Based Compensation	13.27	14.04	16.28	15.37	13.36	13.46
Other Operating Activities	-24.38	-6.76	6.7	12.85	12.21	-85.96
Operating Cash Flow	-11.43	12.8	31.98	64.21	51.78	45.95
Operating Cash Flow Growth	-	-59.98%	-50.19%	24.03%	12.68%	53.23%
Capital Expenditures	-0.34	-0.38	-0.68	-0.55	-1.8	-1.02
Acquisitions	-103.37	-100.67	0	0	0	0
Change in Investments	-113.86	88.99	50.6	-76.14	-39.7	-67.29
Investing Cash Flow	-217.57	-12.06	49.93	-76.7	-41.5	-68.31
Share Issuance / Repurchase	0	0	0.73	3.55	5.63	6.26
Financing Cash Flow	0	0	0.73	3.55	5.63	6.26
Exchange Rate Effect	-0.01	0.05	0.27	-0.09	0.05	-0
Net Cash Flow	-229.01	0.79	82.91	-9.02	15.96	-16.1
Free Cash Flow	-11.77	12.42	31.31	63.66	49.98	44.93
Free Cash Flow Growth	-	-60.33%	-50.83%	27.37%	11.24%	872.89%
Free Cash Flow Margin	-6.63%	6.45%	12.31%	23.69%	20.14%	19.78%
Free Cash Flow Per Share	-0.20	0.22	0.55	1.15	0.92	0.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).